The criteria for accelerated approval include: 1. The drug must treat a serious condition. 2. There must be an unmet medical need. 3. Approval is based on a surrogate or intermediate clinical endpoint.
These criteria ensure that the benefits of accelerated access to new therapies outweigh the risks.
